Mitotane (Lysodren)

A derivative of the insecticide DICHLORODIPHENYLDICHLOROETHANE that specifically inhibits cells of the adrenal cortex and their production of hormones. It is used to treat adrenocortical tumors and causes CNS damage, but no bone marrow depression.

Also Known As:

Networked: 409 relevant articles (41 outcomes, 28 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Terzolo, Massimo: 16 articles (02/2015 - 09/2005)
2.	Fassnacht, Martin: 14 articles (11/2015 - 04/2005)
3.	Allolio, Bruno: 13 articles (11/2015 - 06/2006)
4.	Baudin, Eric: 12 articles (08/2015 - 01/2006)
5.	Berruti, Alfredo: 10 articles (02/2015 - 09/2005)
6.	Young, Jacques: 9 articles (12/2015 - 01/2006)
7.	Leboulleux, Sophie: 9 articles (02/2015 - 01/2006)
8.	Volante, Marco: 7 articles (02/2015 - 12/2008)
9.	Schlumberger, Martin: 7 articles (02/2015 - 01/2006)
10.	Berruti, A: 7 articles (03/2014 - 06/2000)

Related Diseases

1.	Adrenocortical Carcinoma 07/01/2001 - "The excellent follow-up of these patients suggests that even in hopeless cases with metastatic adrenocortical carcinoma, mitotane should be administered for very long periods of time as it can be well-tolerated and may be beneficial in the long run." 01/01/1994 - "Complete remission of metastasized adrenocortical carcinoma under o,p'-DDD." 07/01/1990 - "Unlike previous reports of metastatic adrenal cortical carcinoma in which complete remission was obtained with high dose Mitotane treatment, the dose of Mitotane used in this patient was low. " 06/01/2009 - "Metastatic virilizing adrenocortical carcinoma: a rare case of cure with surgery and mitotane therapy." 01/01/2001 - "For adrenocortical carcinoma, adjunctive treatment with oral mitotane leads to well-documented improvement of survival. "
2.	Neoplasms (Cancer) 02/01/2013 - "Mitotane, an adrenolytic agent, is the mainstay of treatment after surgical removal of the tumor. " 01/01/2009 - "The objective of the study was to profile human adrenal tumors and ACC cell lines to assess activated IGF signaling and determine the efficacy of two IGF receptor (IGF-1R) antagonists alone and in combination with mitotane. " 06/01/1998 - "We conclude that monitoring serum concentrations of mitotane makes long-term treatment possible with few side effects; steroid profile analysis can be used for early detection of tumor recurrence; and repeat surgery for recurrence is of value for patients with long disease-free intervals." 01/01/1982 - "Treatment with methyrapone, o,p'DDD, and irradiation of the tumor resulted in a lasting remission. " 08/01/2015 - "Finally, retrospective study of an ACC cohort of 26 mitotane-treated patients revealed that statin therapy was significantly associated with a higher rate of tumor control. "
3.	Cushing Syndrome 09/01/2011 - "Mitotane is highly effective in the long-term management of Cushing's syndrome but has a slow onset of action. " 10/01/2000 - "Furthermore, we used mitotane with good results in Cushing's syndrome of non-malignant origin as pre-treatment before surgery or in long-term treatment for patients with poor tolerance of other adrenal inhibitors." 04/01/2014 - "The efficacy of adjuvant mitotane does not seem to be influenced by overt hypercortisolism." 03/01/1966 - "Remission in Cushing's syndrome with o,p'-DDD." 01/01/1999 - "[Effects of mitotane therapy in dogs with pituitary dependent Cushing syndrome on the adrenal gland size--an ultrasonographic study]."
4.	Adrenal Cortex Neoplasms (Adrenocortical Cancer) 05/15/1993 - "These findings do not support the conclusion that adjuvant mitotane is beneficial in patients with localized or regional adrenocortical cancer. " 08/16/2012 - "In this study, we explored the molecular effect of mitotane on steroidogenesis in human adrenocortical cancer NCI-H295 cells. " 12/01/2008 - "Seventeen consecutive patients who were treated with mitotane after radical resection of adrenocortical cancer (ACC) from 1999 to 2005 underwent physical examination, routine laboratory evaluation, monitoring of mitotane concentrations, and a hormonal work-up at baseline and every 3 months till ACC relapse or study end (December 2007). " 11/01/2015 - "We report the case of toxic plasma levels with low doses of mitotane in a 47-year-old man with adrenocortical cancer. " 02/05/2015 - "These data demonstrate that RRM1 gene interferes with mitotane metabolism in adrenocortical cancer cells, as a possible mechanisms of drug resistance. "
5.	Neoplasm Metastasis (Metastasis) 12/01/1992 - "Mitotane improved the survival rate only in patients with metastases who received it after operation (vs non-mitotane-treated patients [p < 0.05]). " 03/15/1981 - "He experienced an objective clinical remission and disappearance of pulmonary metastases while receiving o,p'-DDD as the sole chemotherapeutic agent. " 04/01/2012 - "Two months after surgery, she received radiation for suspected lumbar vertebral metastasis and initiated mitotane therapy. " 05/01/2011 - "No metastasis or size increase of the remaining adrenal glands were found suggesting that their hypermetabolic state could be attributed to mitotane treatment. " 06/01/2008 - "The second patient presented with an ACC of 9 cm. After resection, the patient developed liver metastases, which were treated with o,p'-DDD. "

Related Drugs and Biologics

1.	Mitotane (Lysodren)
2.	Aminoglutethimide (Cytadren)
3.	Hydrocortisone (Cortisol)
4.	Ketoconazole (Nizoral)
5.	Metyrapone
6.	Adrenocorticotropic Hormone (ACTH)
7.	Doxorubicin (Adriamycin)
8.	Etoposide (VP 16)
9.	Cisplatin (Platino)
10.	Hormones

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Adrenalectomy
3.	Radiotherapy
4.	Adjuvant Chemotherapy
5.	Pituitary Irradiation